Relmada Therapeutics, Inc. (RLMD) 의 후행 P/E가 마이너스 -8.5, 이는 회사가 현재 후행 12개월(TTM) 기준으로 적자 상태임을 의미합니다. 후행 이익수익률은 -11.80%.
이 페이지에서 입증된 기준:
SharesGrow 종합 점수: 61/100 4/7 개 기준 통과.
| Year | P/E (TTM) | PEG 비율 | P/B 비율 | P/S 비율 | 배당 수익률 |
|---|---|---|---|---|---|
| 2017 | -0.3 | 0.00 | 1.36 | 0.00 | - |
| 2018 | -0.3 | -0.01 | -0.46 | 0.00 | - |
| 2019 | -0.5 | 0.13 | 1.21 | 0.00 | - |
| 2019 | -4.8 | 0.12 | 0.62 | 0.00 | - |
| 2020 | -1.7 | -0.01 | 0.95 | 0.00 | - |
| 2021 | -0.6 | -0.01 | 0.38 | 0.00 | - |
| 2022 | -0.2 | 0.01 | 0.18 | 0.00 | - |
| 2023 | -0.3 | 0.01 | 0.36 | 0.00 | - |
| 2024 | -0.2 | 0.01 | 0.44 | 0.00 | - |
| 2025 | -3.3 | 0.07 | 2.20 | 0.00 | - |
| Year | EPS (희석) | 매출 | 순이익 | 순이익률 |
|---|---|---|---|---|
| 2016 | $-2.08 | $0.00 | $-6.29M | - |
| 2017 | $-2.86 | $0.00 | $-8.96M | - |
| 2018 | $-2.74 | $0.00 | $-17.32M | - |
| 2019 | $-1.63 | $0.00 | $-15.01M | - |
| 2020 | $-3.81 | $0.00 | $-59.46M | - |
| 2021 | $-7.16 | $0.00 | $-125.75M | - |
| 2022 | $-5.30 | $0.00 | $-157.04M | - |
| 2023 | $-3.28 | $0.00 | $-98.79M | - |
| 2024 | $-2.65 | $0.00 | $-79.98M | - |
| 2025 | $-1.45 | $0.00 | $-57.39M | - |
| Year | EPS (평균) | EPS 범위 | 매출 (평균) | 매출 범위 | 애널리스트 수 |
|---|---|---|---|---|---|
| 2026 | $-0.72 | $-0.79 – $-0.60 | $10M | $10M – $10M | 3 |
| 2027 | $-0.92 | $-0.96 – $-0.86 | $32.45M | $32.45M – $32.45M | 2 |
| 2028 | $-0.91 | $-1.17 – $-0.77 | $19M | $19M – $19M | 3 |
| 2029 | $-0.61 | $-0.61 – $-0.61 | $88.4M | $88.4M – $88.4M | 1 |
| 2030 | $-0.39 | $-0.39 – $-0.39 | $144.45M | $144.45M – $144.45M | 1 |
